

A UNIQUE FORMULATION¹

POLYNUCLEOTIDE (PN) 20MG/ML

DNA Optimizing Technology (DOT™)²

Improves the appearance of uneven skin tone

Improves the appearance of skin irregularities

Minimizes pore appearance

Refines the appearance of visible scars



FULL FACE - NECK - DECOLLETE - HANDS



VISCOSITY

PACKAGING **2ml x 2 syringes**

NEEDLE **33G 4mm**




PERIOCCULAR



VISCOSITY

PACKAGING **1ml x 1 syringe**

NEEDLE **34G 4mm**




ATROPHIC SCARS



VISCOSITY

PACKAGING **1ml x 1 syringe**

NEEDLE **30G 8mm**




PROTOCOL AND USE

1 cycle: 3-4 sessions at 3-4 weeks (maximum)


Depth: intradermal

Technique: serial/multi-puncture injections (papulas)

Injection volume : 0.02 - 0.05 ml (0.5~2 cm intervals)



*Illustration for application schedule only.
This diagram does not represent clinical efficacy or treatment outcomes.*







Maintenance:

For REJURAN[®] I and S: once every 3 months

For REJURAN[®]: 1 additional session at 6 months,
1 cycle per 12 months

- This study included 5 Korean women, 2 in their 30s and 3 in their 40s.
- Protocol: 4 injections session at 2-week intervals; were performed intradermally with 33G needle.
- Total of 1 mL per **cheek** injected with ~0.05 mL per injection point.

OBSERVED CHANGES IN SKIN APPEARANCE



- Improvements in the appearance of pores and skin texture were more noticeable in subjects in their 30s.
- Improvements in the appearance of skin tone and overall skin appearance were more noticeable in subjects in their 40s.

SKIN APPEARANCE RESULTS



BEFORE




AFTER

@Copyright: Vira Melnyk



BEFORE



AFTER

@Copyright: Valeria Zavorin

1. [DB00000] REJURAN information for use.

2. Patent No. : 10-0986603

3. Park.K and al. Long-chain polynucleotide filler for skin rejuvenation: efficacy and complications in five patients. Dermatologic Therapy. 2016 Jan-Feb;29(1):37-40. doi: 10.1111/dth.12299

Rejuran®, Rejuran® i, and Rejuran® s are Class III medical devices, regulated health products bearing the CE marking (CE 2265). Rejuran®, Rejuran® i, and Rejuran® s are intended to promote tissue restoration and reconstruction, as well as the improvement of physical appearance on the face, neck, décolleté, and hands. These products are only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law. Consult the IFU before injection. Any serious side effects occurring in relation to the product should be reported without delay to Laboratoires VIVACY (customer.complaint@vivacy.fr) and to the national health authority of the country in which the patient is established. Manufacturer: PharmaResearch 77-19, Gwahakdanji-ro, Gangneung-si, Gangwon-do, Korea. MK1357 vA (12.2025)